Next Article in Journal
Correction: Odegaard et al. Distinct Synaptic Vesicle Proteomic Signatures Associated with Pre- and Post-Natal Oxycodone-Exposure. Cells 2022, 11, 1740
Previous Article in Journal
Direct Binding of Synaptopodin 2-Like Protein to Alpha-Actinin Contributes to Actin Bundle Formation in Cardiomyocytes
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Raha et al. Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor α. Cells 2023, 12, 2791

1
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
2
Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, 820 South Damen Avenue, Chicago, IL 60612, USA
*
Author to whom correspondence should be addressed.
Cells 2024, 13(16), 1374; https://doi.org/10.3390/cells13161374
Submission received: 2 July 2024 / Accepted: 15 July 2024 / Published: 19 August 2024
Error in Figure 4
In the original publication [1], there was a mistake in Figure 4. One image was incorrectly provided for the Non-Tg (upper left panel) group of Figure 4E that had an overlap with Figure 4C—PAS. This happened due to the simultaneous processing of numerous images, involving contrasting and cropping, while working with multiple open windows on a laptop. It has now been corrected. Please see the corrected Figure 4E below.
Figure 4. Treatment with GFB attenuates neuronal apoptosis and reduces glycoconjugates in Tay–Sachs mice. Three-month-old TS mice (n = 6/group) were orally administered with GFB (8 mg/kg/d) solubilized in 0.5% methylcellulose. Therefore, control TS mice received 0.5% methylcellulose as a vehicle. After 2 months of treatment, cortical sections were stained for TUNEL (A). TUNEL (+ve) cells were expressed as a % of total cells per square mm (B). Paraffin-embedded cerebral cortex sections were subjected to periodic acid-Schiff (PAS) stain for analyzing glycolipids (C). The glycoconjugate material -stained magenta is shown by the arrow and quantified for PAS +ve cells per mm square (D). Paraffin-embedded sections were also subjected to H & E staining as characterized by large vacuoles (thick arrows), pyknotic nuclei, and swollen neuron in TS mice (E). The number of vacuoles was quantified per mm square (F). Results represent counting three different sections from 3 different mice (n = 3) per group. All data represented as mean ± SEM. All statistical analyseis were as performed by one-way ANOVA, followed by Dunnett’s multiple comparison test. *** p < 0.001.
Figure 4. Treatment with GFB attenuates neuronal apoptosis and reduces glycoconjugates in Tay–Sachs mice. Three-month-old TS mice (n = 6/group) were orally administered with GFB (8 mg/kg/d) solubilized in 0.5% methylcellulose. Therefore, control TS mice received 0.5% methylcellulose as a vehicle. After 2 months of treatment, cortical sections were stained for TUNEL (A). TUNEL (+ve) cells were expressed as a % of total cells per square mm (B). Paraffin-embedded cerebral cortex sections were subjected to periodic acid-Schiff (PAS) stain for analyzing glycolipids (C). The glycoconjugate material -stained magenta is shown by the arrow and quantified for PAS +ve cells per mm square (D). Paraffin-embedded sections were also subjected to H & E staining as characterized by large vacuoles (thick arrows), pyknotic nuclei, and swollen neuron in TS mice (E). The number of vacuoles was quantified per mm square (F). Results represent counting three different sections from 3 different mice (n = 3) per group. All data represented as mean ± SEM. All statistical analyseis were as performed by one-way ANOVA, followed by Dunnett’s multiple comparison test. *** p < 0.001.
Cells 13 01374 g001
Wrong Model
We would also like to report an error in the strain of the animals that was said to have been used in this study. Throughout the study, we used B6;129S4-Hexbtm1Rlp/J mice lacking the Hexb gene, which model a severe form of Tay–Sachs (Sandhoff) disease.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Raha, S.; Dutta, D.; Paidi, R.K.; Pahan, K. Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor α. Cells 2023, 12, 2791. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Raha, S.; Dutta, D.; Paidi, R.K.; Pahan, K. Correction: Raha et al. Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor α. Cells 2023, 12, 2791. Cells 2024, 13, 1374. https://doi.org/10.3390/cells13161374

AMA Style

Raha S, Dutta D, Paidi RK, Pahan K. Correction: Raha et al. Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor α. Cells 2023, 12, 2791. Cells. 2024; 13(16):1374. https://doi.org/10.3390/cells13161374

Chicago/Turabian Style

Raha, Sumita, Debashis Dutta, Ramesh K. Paidi, and Kalipada Pahan. 2024. "Correction: Raha et al. Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor α. Cells 2023, 12, 2791" Cells 13, no. 16: 1374. https://doi.org/10.3390/cells13161374

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop